Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Syntansine
- Development stage
- Unknown
- Lead developer
- Lonza
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Syntansine is a proprietary linker-payload component developed by Synaffix (now a Lonza company) for the construction of antibody-drug conjugates (ADCs). It is a key element of the toxSYN platform and features a maytansinoid payload, specifically Ahx-maytansine, which acts as a potent microtubule inhibitor. The payload is conjugated via a cleavable valine-citrulline (vc) linker and a PABC (p-aminobenzyloxycarbonyl) group, incorporating Synaffix's HydraSpace polar spacer technology. This technology is designed to enhance the stability, solubility, and therapeutic index of ADCs. Syntansine is typically attached to antibodies using GlycoConnect, a site-specific glycan conjugation method that ensures a highly uniform drug-to-antibody ratio (DAR). Preclinical evaluations of ADCs utilizing Syntansine, such as a trastuzumab-based conjugate, have demonstrated superior efficacy and safety profiles compared to conventional ADCs like Kadcyla.
- Brand names
- SYNtansine
- Other names
- BCN-HydraSpace-vc-PABC-Ahx-maytansine
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on Syntansine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Syntansine.